Canada

Dashboard Indicators

  • Long-term Control of Eczema Symptoms

    Scores are based on responses to the AD Control Tool: https://www.adcontroltool.com/adct-how-to-use/adct-in-clinical-practice

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Satisfaction with Eczema Treatments

    Self reported satisfaction with current treatments (caregivers and adults).

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Life Span Trade-Off (Health Utility)

    Percent of remaining life span adult patients would trade off in order to be restored to perfect health. (Derived from EQ5D Utility Scores).

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Eczema Patients Self Reported Health to Compared to Country Average

    Self-rated quality of life score for the average person compared to the self-rated quality of life score for adults with eczema.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Dimensions of Health – Relative Impact (Adults)

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Financial Burden – Impacts

    Percent of respondents (adults and caregivers) who reported using savings, borrowing money and/or reducing spending due to eczema. Higher = More Financial Impact

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Shared Decision Making

    The percentage of respondents who indicated that the healthcare provider whom they see for eczema asked about their priorities for their eczema care at the most recent visit.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Eczema Education and Training

    Respondents who said a health care provider had ever suggested they attend an eczema training program that happens after the office visit.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Access to Dermatologists

    Canada ranked 9th out of the 10 countries in access to dermatologists. A lack of dermatologists to serve the population likely affects wait times.

    Source: “Number of Physicians by Province/Territory and Specialty, Canada .” Canadian Medical Association, 2019. www.cma.ca/canadian-physician-data.

  • Evidence-Based Guidelines

    Canada lacks its own practice guidelines for eczema. The Eczema Society of Canada guide published in 2020 is a starting point for future guideline development efforts.

    Scoring criteria for the guideline measure >

    Source: Weinstein, Miriam, et al. “Atopic Dermatitis: A Practical Guide to Management 2020.” ESC Health Provider Resources , Eczema Society of Canada , 2021, Atopic Dermatitis: A Practical Guide to Management 2020.

Literature Review Key Findings

 

The prevalence of AD in Canadian adults is lower than in other countries such as the US, but the prevalence of AD in Canadian children has been increasing in recent years. Recent data suggests a substantially higher AD burden in Canada’s indigenous population. Population-based studies of comorbidities associated with AD in Canadians are lacking, suggesting a potential area for further research. 

A pair of cross-sectional surveys conducted by the Eczema Society of Canada have done much to describe the burden of AD among both Canadian adults and children (and their caregivers) with moderate-to-severe AD. Sleep loss and mental health comorbidities were seen in adults, children, and caregivers. Finally, access to specialized dermatologic care is a widespread problem for both Canadian children and adults with AD. 

Learn more about the findings gathered from the Canada literature review.